Anonymous
Guest
Anonymous
Guest
BRIEF-Solvay says subsidiary will not to file patent infringement suit against Perrigo Israel Pharmaceuticals
BRUSSELS, July 17 (Reuters) - Solvay SA (Brussels: SOLB.BR - news) :
* Says its unimed pharmaceuticals LLC subsidiary will not to file a patent
infringement suit against Perrigo Israel Pharmaceuticals, ltd
* Says Unimed received a letter from Perrigo (NASDAQ: PRGO - news) advising Unimed that Perrigo had filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market and sell a generic version of AndroGel (testosterone gel) 1% CIII in the U.S. prior to the expiration of Unimed's patent
* Says the receipt of these letters triggered a 45-day period during which time the company could have initiated patent infringement litigation and triggered a 30-month stay of FDA approval of Perrigo's ANDA
* Says in its letter to the company, Perrigo asserted that it did not infringe the AndroGel patent because its proposed testosterone gel product contains a different formulation than the formulation protected by the AndroGel patent
* Says the company does not waive its right to initiate patent infringement litigation at a later stage based on new or additional facts and circumstances
((Brussels newsroom)
BRUSSELS, July 17 (Reuters) - Solvay SA (Brussels: SOLB.BR - news) :
* Says its unimed pharmaceuticals LLC subsidiary will not to file a patent
infringement suit against Perrigo Israel Pharmaceuticals, ltd
* Says Unimed received a letter from Perrigo (NASDAQ: PRGO - news) advising Unimed that Perrigo had filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market and sell a generic version of AndroGel (testosterone gel) 1% CIII in the U.S. prior to the expiration of Unimed's patent
* Says the receipt of these letters triggered a 45-day period during which time the company could have initiated patent infringement litigation and triggered a 30-month stay of FDA approval of Perrigo's ANDA
* Says in its letter to the company, Perrigo asserted that it did not infringe the AndroGel patent because its proposed testosterone gel product contains a different formulation than the formulation protected by the AndroGel patent
* Says the company does not waive its right to initiate patent infringement litigation at a later stage based on new or additional facts and circumstances
((Brussels newsroom)